Provided by Tiger Trade Technology Pte. Ltd.

Aldeyra Therapeutics

1.23
-0.0900-6.82%
Volume:1.65M
Turnover:2.12M
Market Cap:74.00M
PE:-3.21
High:1.35
Open:1.34
Low:1.22
Close:1.32
52wk High:5.93
52wk Low:1.07
Shares:60.16M
Float Shares:48.93M
Volume Ratio:0.96
T/O Rate:3.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3836
EPS(LYR):-0.5636
ROE:-49.48%
ROA:-22.70%
PB:1.95
PE(LYR):-2.18

Loading ...

Top Executive Makes Bold Insider Move at Aldeyra Therapeutics

TIPRANKS
·
Jun 06

Aldeyra Therapeutics CEO Todd C. Brady acquires 250,000 common shares worth $418,450

Reuters
·
Jun 06

3 Promising Penny Stocks With Market Caps Reaching $300M

Simply Wall St.
·
Jun 05

Aldeyra Therapeutics CEO joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
Jun 02

Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims

TIPRANKS
·
May 27

Aldeyra Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Aldeyra Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
May 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 30

3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%

Simply Wall St.
·
Apr 30

Aldeyra Therapeutics announces annual shareholder meeting

Reuters
·
Apr 28

April 2026's Top 3 Stocks That May Be Trading Below Estimated Fair Value

Simply Wall St.
·
Apr 28

Aldeyra Therapeutics Faces Securities Lawsuit Over Reproxalap Trial Disclosures

TIPRANKS
·
Apr 23

Aldeyra Therapeutics Announces Upcoming Board Member Departure

TIPRANKS
·
Apr 21

Aldeyra director Martin Joyce will not stand for re-election at annual meeting

Reuters
·
Apr 21

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky

TIPRANKS
·
Apr 17

Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data

TIPRANKS
·
Apr 03